Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conferees Kill Corporate AMT In Tax Bill, Freeing Use Of R&D Credits

Executive Summary

Members of a tax reform bill conference committee repealed a controversial corporate alternative minimum tax, which will allow more device firms to take advantage of research & development tax credits. That was one of several changes made to help win the tax bill's final passage, anticipated this week.

You may also be interested in...



Voters Likely To Pick And Choose Among Device Industry Favorites In Close Races

Among the very tight Republican and Democrat contests anticipated in this November’s US midterm elections are more than a few device industry-favored candidates, according to a review of the incumbents’ voting records and recent polling data.

Hello Device Tax, We Hardly Missed You: Companies Seek IRS Action To Stall Tax

With congressional options exhausted for 2017, industry hopes for IRS relief from the device-tax reality, either with a temporary waiver of deposit penalties or some broader tax-enforcement delay.

Puerto Rico Tax-Haven Status, R&D Credit Weakened By Tax-Reform Bill

Under tax reform legislation recently passed by Congress, a 20% tax on products made in domestic territories will adversely affect the many device firms with Puerto Rican plants that currently enjoy a lower, 4% tax rate on profits. And a second tax provision usually relied upon by medtech companies, the R&D tax credit, also loses ground under the final Senate bill passed Dec. 2.

Related Content

Topics

UsernamePublicRestriction

Register

MT121921

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel